Investors should monitor upcoming catalysts including medical meeting presentations of givastomig data in 2026 and initiation of Phase 2b studies for VIS-101 in H2 2026. The strong clinical data and cash runway through 2028 provide significant optionality for value creation.
Price Chart
Executive Summary
NovaBridge reported strong clinical progress in 2025 with compelling data for its lead candidates givastomig and VIS-101, demonstrating robust efficacy and safety. The company has a solid cash position of $210.8 million supporting operations through 2028, following its transformation into a global biotech platform.
Key Facts
- Givastomig showed 75% objective response rate and 16.9-month median progression-free survival in gastric cancer trials
- VIS-101 demonstrated rapid, robust, and durable responses in wet-AMD with ~two-thirds of patients retreatment-free at four months
- Company has $210.8 million in cash as of December 31, 2025, supporting operations through 2028
- Givastomig has potential eligibility for FDA Accelerated Approval Pathway with Phase 3 trial potentially starting as early as YE 2026
- VIS-101 expected to begin Phase 2b studies in H2 2026
Financial Impact
The company reported $210.8 million in cash, cash equivalents, and short-term investments as of December 31, 2025, with R&D expenses of $62.9 million for 2025 compared to $21.8 million in 2024.
Risk Factors
- Clinical trial results may not be replicated in larger studies
- Regulatory approval is not guaranteed despite potential eligibility for Accelerated Approval Pathway
- High R&D expenses may continue to increase cash burn
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-145700 |
| Document: nbp-ex99_2.htm | 0001193125-26-145700 |
| Document: 20-f_pr_and_ir_deck_-_04.htm | 0001193125-26-145700 |
| Document: 0001193125-26-145700-index-headers.html | 0001193125-26-145700 |
| Document: 0001193125-26-145700-index.html | 0001193125-26-145700 |
| Document: 0001193125-26-145700.txt | 0001193125-26-145700 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $1.49 | awaiting T+5 | — | $1.22 (−18.46%) |
Oct 25, 2026 1d ago | Press Release | $1.42 | awaiting T+5 | — | $1.22 (−14.44%) |
Oct 23, 2026 3d ago | 6-K | $1.37 | awaiting T+5 | — | $1.22 (−11.31%) |
Oct 13, 2026 13d ago | 6-K | $1.29 $1.43 | ▲ +10.47% | ▲ +11.62% | $1.22 (−5.81%) |
Sep 8, 2026 6w ago | 6-K | $1.78 $1.61 | ▼ −9.55% | ▼ −8.89% | $1.22 (−31.74%) |
Sep 8, 2026 6w ago | 6-K | $1.78 $1.61 | ▼ −9.55% | ▼ −8.89% | $1.22 (−31.74%) |
Aug 20, 2026 9w ago | 6-K | $1.91 $1.89 | ▲ +1.05% | ▲ +2.16% | $1.22 (+36.39%) |
Aug 20, 2026 9w ago | 6-K | $1.91 $1.89 | ▼ −1.05% | ▼ −2.16% | $1.22 (−36.39%) |
Aug 20, 2026 9w ago | Press Release | $1.91 $1.89 | ▲ +1.05% | ▲ +2.16% | $1.22 (+36.39%) |
Jul 24, 2026 13w ago | 6-K | $1.78 $1.60 | ▼ −10.11% | ▼ −11.19% | $1.22 (−31.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers